According to the CALGB 8903 study published in the Journal of Clinical Oncology, patients with stage III colon cancer who eat at least 2 servings of nuts per week have higher disease-free survival (DFS) and overall survival (OS). The association between total nut intake and improved outcomes is consistent among other known or suspected risk factors for cancer recurrence and death.
Dr. Charles S. Fuchs of the Yale Cancer Center and colleagues wrote: “This prospective study of patients with stage III colon cancer shows that a diet with increased nut consumption is associated with a significant reduction in cancer recurrence and mortality. Although we observed The results of sex studies cannot determine causality, but the results further support diet and lifestyle as modifiable risk factors for patients with colon cancer. “
This study conducted a 6.5-year follow-up survey of 826 colon cancer patients treated with surgery and chemotherapy. The results showed that people who consumed at least two ounces of nuts per week had a 42% increase in disease-free survival and an increase in overall survival. 57%.
The researchers said: “Further analysis of the cohort showed that the disease-free survival of participants who consumed nuts significantly increased. Nuts include almonds, walnuts, hazelnuts, cashews, walnuts, etc. On the contrary, peanuts are actually a type of bean food . These results are consistent with other observational studies that show that a range of health behaviors, including increasing physical activity, maintaining a healthy weight, and lower intake of sugar and sweet drinks can increase the survival rate of colon cancer. “
The findings emphasize the importance of diet and lifestyle factors in the survival of colon cancer. In addition, the researchers emphasized that the study emphasized the connection between biological mechanisms of not only colon cancer but also certain chronic diseases, such as type 2 diabetes, which worsens the disease.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
